Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems

Lead Candidate Shelved

 
• By Andrew McConaghie
DNA helix
The company's ex vivo lentiviral gene therapy platform has hit an obstacle in Fabry disease - but it hopes other rare diseases will deliver. • Source: Alamy

More from R&D

More from Scrip